Arthritis & Rheumatism, Volume 60,
October 2009 Abstract Supplement

The 2009 ACR/ARHP Annual Scientific Meeting
Philadelphia October 16-21, 2009.


ADAMTS5 Is a Biomarker for Prediction of the Response to Infliximab in Patients with Rheumatoid Arthritis

Tsuzaka1,  Kensei, Itami1,  Yuka, Amano2,  Koichi, Takeuchi3,  Tsutomu

Ichikawa General Hospital, Tokyo Dental College, Ichikawa, Chiba, Japan,
Saitama Medical Center, Saitama Medical School, Kawagoe, Saitama, Japan,
Keio University School of Medicine, Tokyo, Japan

Purpose:

To identify a biomarker for prediction of the response to infliximab (INF) in rheumatoid arthritis patients, we focused on a disintegrin and metalloproteinase with thrombospondin motifs 5 (ADAMTS5) that seems to play a key role in aggrecan degradation in cartilage.

Method:

Fourty-four randomly selected active RA patients were treated with INF. Peripheral blood samples were collected at baseline and ADAMTS5 mRNA was quantified using real-time PCR.

Results:

Baseline ADAMTS5 mRNA levels in the responder (1.461 ± 0.817) was significantly (p=0.0090) lower than that in the non-responder (2.246 ± 1.350) at 62 weeks' treatment with INF. The DAS28 at 62 weeks' treatment was significantly (p=0.0003) lower in the Low-ADAMTS5 group (2.47 ± 1.50) than in the High-ADAMTS5 group (4.46 ± 1.76). The percent reduction of the DAS28 (%DAS28 reduction) was significantly (p=0.0015) higher in the Low-ADAMTS5 group (52.8 ± 7.25) than in the High-ADAMTS5 group (22.5 ± 5.21). Interestingly, significant correlations were observed between the DAS28 and %DAS28 reduction at 62 weeks (p<0.001; r= 0.56 and -0.60, respectively) and the baseline ADAMTS5 mRNA level. Furthermore, DHAQ, an estimate of the improvement in the HAQ score, at 62 weeks' treatment was significantly (p=0.0305) higher in the Low-ADAMTS5 group (0.70 ± 0.68) than in the High-ADAMTS5 group (0.25 ± 0.35). The positive predictive value of a low baseline ADAMTS5 level for predicting good response and remission (DAS28<2.6 at 62 weeks) was 80.0% and 73.3%, respectively.

Conclusion:

The baseline ADAMTS5 mRNA level is a candidate biomarker for prediction of the response to INF in RA patients.

To cite this abstract, please use the following information:
Tsuzaka, Kensei, Itami, Yuka, Amano, Koichi, Takeuchi, Tsutomu; ADAMTS5 Is a Biomarker for Prediction of the Response to Infliximab in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheum 2009;60 Suppl 10 :918
DOI: 10.1002/art.25997

Abstract Supplement

Meeting Menu

2009 ACR/ARHP